COZMOS: Phase I/Ib trial of Combined 5’azacitidine and carboplatin for recurrent/refractory paediatric brain and solid tumours
Brain and solid tumours
Status:
Closed to Recruitment
New treatment options for children with relapsed and recurrent brain and solid tumours is limited. Recent research shows that many of these tumours have a general change in their DNA (methylation), and altering methylation may stop the tumours. This international trial will test the safety of treating children with a methylation inhibitor (azacitidine) and a standard chemotherapy drug (carboplatin), in the first step of exploring this new treatment option.
Disease stage: Relapsed and recurrent cancers
Patient age range: 1-18 years old
Trial sponsors:
- National: ANZCHOG
- International: Hospital for Sick Children, Toronto.
